secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001104659-26-008698
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal gains full control over Rezdiffra patent term extensions from Roche
----------------------------------------------------------------------------

- Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.
- Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.
- Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.
- Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/0001104659-26-008698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/tm264540d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer